FDA moves closer to approving MDMA [sassafras]
Although often overshadowed by its reputation as a dangerous “party” drug, MDMA has long been recognized by the mental-health clinicians for its therapeutic benefit.
But there remains a conflict between the DEA, which contends MDMA has no medical benefits, and the medical community, which considers the DEA’s scheduling a “largely blind decision.” Historically, disagreements between pioneering medical science and restrictive government policy have largely favored the latter. Fortunately, several current events in drug policy point toward liberalization. President Trump recently signed national right-to-try legislation into law, allowing terminally ill patients access to experimental drugs before they are approved.